Success of tocilizumab in RA patients with remission induction and sustained efficacy after discontinuation.

Trial Profile

Success of tocilizumab in RA patients with remission induction and sustained efficacy after discontinuation.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jan 2016

At a glance

  • Drugs Tocilizumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SURPRISE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jan 2016 Results published in the Annals of the Rheumatic Diseases
    • 15 Jun 2013 Results presented at the 14th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top